On January 26^th, 2025, Zonhonbio's Class I new chemical drug—ZHB601 for Injection received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA). ZHB601 for Injection is an original innovation developed by Zonhonbio, with complete independent intellectual property rights both domestically and internationally. The approved indication for this drug is cerebral small vessel disease.